Nektar Therapeutics (NKTR) closed at $37.45 on October 26, 2026, up 0.6% from the previous close, on volume of 512,908 shares (30-day average 1,606,272).
Data as of October 26, 2026.
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PRNewswire (Fri, 23-Oct 4:16 PM ET)
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks (Thu, 22-Oct 7:58 AM ET)
/UPDATE -- Nektar Therapeutics/
PRNewswire (Thu, 1-Oct 9:44 AM ET)
Market Chameleon (Thu, 1-Oct 3:59 AM ET)
PRNewswire (Thu, 1-Oct 7:30 AM ET)
PRNewswire (Wed, 30-Sep 10:30 AM ET)
PRNewswire (Mon, 28-Sep 8:01 AM ET)
Market Chameleon (Tue, 25-Aug 5:16 AM ET)
PRNewswire (Tue, 25-Aug 8:31 AM ET)
Nektar Therapeutics Announces Second Quarter 2026 Financial Results
PRNewswire (Thu, 13-Aug 4:15 PM ET)
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
Nektar Therapeutics trades on the NASDAQ stock market under the symbol NKTR.
As of October 26, 2026, NKTR stock price climbed to $37.45 with 512,908 million shares trading.
NKTR has a beta of 1.19, meaning it tends to be more sensitive to market movements. NKTR has a correlation of 0.03 to the broad based SPY ETF.
NKTR has a market cap of $1.28 billion. This is considered a Small Cap stock.
Last quarter Nektar Therapeutics reported $10 million in Revenue and -$1.23 earnings per share. This fell short of revenue expectation by $-405,376 and exceeded earnings estimates by $.81.
In the last 3 years, NKTR traded as high as $109.00 and as low as $6.19.
The top ETF exchange traded funds that NKTR belongs to (by Net Assets): VTI, XBI, IWM, VXF, VTWO.
NKTR has underperformed the market in the last year with a price return of -41.2% while the SPY ETF gained +15.1%. NKTR has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -46.0% and -9.0%, respectively, while the SPY returned +3.9% and -1.7%, respectively.
NKTR support price is $35.62 and resistance is $38.82 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NKTR shares will trade within this expected range on the day.
